이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Neonatal AI-Based Early Warning System for Late-Onset Sepsis and Necrotizing Enterocolitis in the NICU: Assessment of Response and Effectiveness (NEO-AWARE)

2026년 11월 5일 업데이트: Karlijn Van Damme, University Hospital, Antwerp

Neonatal AI-Based Early Warning System for Late-Onset Sepsis and Necrotizing Enterocolitis in the NICU: Assessment of Response and Effectiveness in a Post-Implementation Prospective Study With Pre-Implementation Historical Comparison

This study aims to evaluate the Intellicens software, an artificial intelligence (AI)-based early warning system designed to help doctors and nurses detect serious complications in premature babies at an early stage. These complications include bloodstream infections (sepsis) and necrotizing enterocolitis (NEC), a serious condition affecting the intestines.

The study will involve babies born before 32 weeks of pregnancy who are admitted to the Neonatal Intensive Care Unit (NICU). The Intellicens Neo model analyses routinely collected medical data, such as heart rate, to identify patterns that may indicate an increased risk of sepsis or NEC and generate an early warning for healthcare professionals. The treating doctor remains responsible for deciding whether further examinations or treatment are needed.

The software has previously been tested using data from babies who had already been discharged from hospital, with promising results. This study will evaluate how well the software performs in real-life clinical practice during the hospital stay.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

500

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Amsterdam, 네덜란드
        • Amsterdam UMC
      • Rotterdam, 네덜란드
        • Erasmus MC Rotterdam
    • Antwerp
      • Edegem, Antwerp, 벨기에, 2650
        • Antwerp University Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 어린이
  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Neonates born below a gestational age of 32 weeks
  • Admitted to the NICU
  • Written informed consent

Exclusion Criteria:

  • Severe congenital malformations
  • Admission for palliative care

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Intellicens Neo implementation group

Preterm infants born at less than 32 weeks of gestational age admitted to participating neonatal intensive care units (NICUs) after implementation of Intellicens Neo. The software generates visual alerts for potential late-onset sepsis (LOS) and necrotizing enterocolitis (NEC). Alerts are visible to the clinical care team, while clinical assessment and treatment decisions remain at the discretion of the treating clinicians. Study outcomes will be compared with a historical pre-implementation dataset.

Intellicens Neo is investigational medical device software designed to support early warning of late-onset sepsis (LOS) and necrotizing enterocolitis (NEC) in preterm infants admitted to the neonatal intensive care unit (NICU). The software calculates a NeoSep Index every 30 minutes and generates visual alerts when predefined alert criteria are met. The alerts are made visible to the clinical care team to support awareness of potential LOS or NEC. Clinical assessment and treatment decisions remain at the discretion of the treating clinicians. The intervention is evaluated in a prospective, multicenter, post-implementation clinical investigation, with outcomes compared with a pre-implementation historical dataset.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
The time between the last Intellicens Neo visual alert preceding LOS/NEC diagnosis and the timepoint of administration of IV antibiotics.
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The time interval between the last Intellicens Neo visual alert preceding the diagnosis of late-onset sepsis (LOS) or necrotizing enterocolitis (NEC) and the administration of intravenous antibiotics for that episode. This outcome evaluates whether the availability of Intellicens Neo alerts is associated with earlier initiation of antibiotic treatment in preterm infants with LOS or NEC.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts acknowledged by the clinical care team within 3 hours.
기간: Within 3 hours after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.

Primary outcome in the substudy, analysis done only in the first 150 patients enrolled. The proportion of Intellicens Neo visual alerts that are acknowledged by the clinical care team within 3 hours after the visual alert is generated.

Within 3 hours after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.

2차 결과 측정

결과 측정
측정값 설명
기간
The time between the last Intellicens Neo visual alert preceding LOS/NEC diagnosis and the timepoint of LOS/NEC diagnosis.
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The time interval between the start of the last Intellicens Neo visual alert preceding a LOS/NEC episode and the time of LOS/NEC diagnosis. The time of diagnosis is defined as the time of the blood culture order in the patient's electronic health record.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Incidence of severe LOS/NEC.
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Occurrence of severe late-onset sepsis (LOS) or necrotizing enterocolitis (NEC) episodes in the study population. The number of severe LOS/NEC episodes will be compared between the prospective cohort and the pre-implementation historical cohort.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Length of NICU stay
기간: From birth until NICU discharge, with an estimated maximum of 25 weeks.

Total duration of the patient's stay in the neonatal intensive care unit (NICU), measured from NICU admission to NICU discharge.

From birth until NICU discharge, with an estimated maximum of 25 weeks.
Total duration of intravenous antibiotic therapy
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Total number of days of intravenous antibiotic treatment during the patient's NICU stay.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Number of suspected LOS episodes
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Total number of suspected late-onset sepsis (LOS) episodes recorded during the patient's NICU stay.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
LOS/NEC-related mortality
기간: Within 7 days after LOS/NEC diagnosis.

Occurrence of mortality related to late-onset sepsis (LOS) or necrotizing enterocolitis (NEC), defined as mortality occurring within 7 days after LOS/NEC diagnosis.

Within 7 days after LOS/NEC diagnosis.
Performance of the Intellicens Neo software device ML model on the prospective dataset: sensitivity
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Performance of the Intellicens Neo software device ML model on the prospective dataset, defined as the sensitivity/recall of the ML model: the percentage of detected LOS/NEC episodes by the Intellicens Neo software device

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Performance of the Intellicens Neo software device ML model on the prospective dataset: specificity
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Performance of the Intellicens Neo software device ML model on the prospective dataset, defined as the specificity of the ML model

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Performance of the Intellicens Neo software device ML model on the prospective dataset: precision
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Performance of the Intellicens Neo software device ML model on the prospective dataset, defined as the precision of the ML model: the amount of (false positive) visual alerts generated by the Intellicens Neo software device represented by the total number of 24-hour time-windows in which a false positive visual alert occurred

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Performance of the Intellicens Neo software device ML model on the prospective dataset: visual alert rate
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Performance of the Intellicens Neo software device ML model on the prospective dataset, defined as the visual alert rate of the ML model: total number of alert days per patient per week.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Number needed to predict
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Number of patients who need to be examined to detect one patient with the relevant disease (LOS or NEC).

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Time from LOS/NEC diagnosis to intravenous antibiotic treatment
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The time interval between the time of LOS/NEC diagnosis, defined as the time of the blood culture order in the patient's electronic health record, and the time of intravenous antibiotic treatment, defined as the time of the order of the first dose of intravenous antibiotics in the patient's electronic health record.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts acknowledged by the clinical care team within 1 hour
기간: Within 1 hour after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are acknowledged by the clinical care team within 1 hour after the visual alert is generated.

Within 1 hour after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts acknowledged by the clinical care team within 6 hours
기간: Within 6 hours after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are acknowledged by the clinical care team within 6 hours after the visual alert is generated.

Within 6 hours after each visual alert during the NICU stay. From postnatal day 3, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts acknowledged by the clinical care team
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The proportion of all Intellicens Neo visual alerts that are acknowledged by the clinical care team, irrespective of the time taken to acknowledge them.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts leading to clinical action
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are followed by a clinical action related to suspected LOS or NEC.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts leading to laboratory evaluation for LOS/NEC suspicion
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are followed by laboratory evaluation for suspected late-onset sepsis (LOS) or necrotizing enterocolitis (NEC).

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts leading to initiation of intravenous antibiotic treatment
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are followed by initiation of intravenous antibiotic treatment for suspected LOS or NEC.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Proportion of Intellicens Neo visual alerts dismissed by the clinical care team
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The proportion of Intellicens Neo visual alerts that are dismissed by the clinical care team.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Time from Intellicens Neo visual alert to the first related clinical action
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

The time interval between an Intellicens Neo visual alert and the first clinical action related to that alert.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Association between time of day and time to visual alert acknowledgement
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Evaluation of the effect of time of day on the time to acknowledgement of Intellicens Neo visual alerts. Time periods are defined as day shift (08:30-17:00), evening shift (17:00-23:00), and night shift (23:00-08:30).

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.
Substudy: Association between Intellicens Neo alert burden and time to visual alert acknowledgement
기간: From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

Evaluation of the effect of alert burden on the time to acknowledgement of Intellicens Neo visual alerts. Alert burden is defined as the presence of at least 2 visual alerts in the same patient during the preceding week.

From postnatal day 3 until NICU discharge, with an estimated maximum of 25 weeks.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 9일

기본 완료 (추정된)

2028년 3월 31일

연구 완료 (추정된)

2028년 3월 31일

연구 등록 날짜

최초 제출

2026년 10월 31일

QC 기준을 충족하는 최초 제출

2026년 11월 5일

처음 게시됨 (실제)

2026년 11월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CTMS 4631
  • CIV-26-06-059054 (기타 식별자: EUDAMED Number)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .